Burcon Nutrascience

Founded in 2012, we are focused on researching, developing, and commercializing breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. With our multi-disciplinary experience in engineering, material science, oncology, medical science, regulatory, finance, business development, sales, marketing, and clinical study coordination we are staffed with the talent to drive the next level of technology for personalized healthcare in oncology.

PhenoTips is a computer software company that provides solution for clinical genetics, phenotyping, and human phenotype ontology. It offers smart software solutions streamlined for clinical use that can be integrated with existing electronic health records. The company was founded in 2014 and headquartered in Ontario, Canada.

Reunion Neuroscience is a pharmaceutical company in the clinical stage that is working on creating treatments for mental health conditions that are often neglected. Their main product, RE104, is a unique psychedelic compound that works on serotonin receptors and is being studied as a potential quick-acting and long-lasting antidepressant for patients with postpartum depression and other mental health issues. Additionally, Reunion is also working on the RE200 series, which consists of compounds that have the potential for more targeted serotonin receptor activity and less psychoactive effects, making them suitable for use in more long-term treatment plans and for a wider range of conditions.

Thryv Therapeutics Inc., formerly known as LQT Therapeutics Inc., is a privately owned company located in Montreal, Quebec, Canada. Since 2019, they have been leading the way in precision medicine for treating Long QT Syndrome through SGK1 inhibition and have expanded their focus to include resistant and rare cancer treatments. The development of SGK1 inhibitors presents a new and innovative approach to targeting treatment-resistant cancers, while also complementing existing therapies. This strategic shift has resulted in an additional $15 million in financing, which will support Thryv in completing a proof-of-concept study for LQTS and submitting an IND for resistant cancer treatment.

For the Quebec and Canadian markets, Cannara Biotech Inc. (TSXV: LOVE) is a vertically integrated producer of premium-grade cannabis and cannabis-derived goods. Delivering "AAAA" products of craft-quality at disruptive retail prices, rotating rare genomes continuously, engaging the community, and being transparent all contribute to the company's value proposition. Cannara owns two enormous facilities in Quebec totaling more than 1,650,000 square feet, taking advantage of the region's affordable labour and electricity costs to produce up to 125,000 kg of cannabis annually.

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting worldwide unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs which could be from plant materials, algae, macroscopic fungi, and combinations thereof. This strategy is supported by FDA set of regulatory guidelines, favouring a more efficient drug development pathway for prescription botanical drug products.

ProMIS Neurosciences is a biotechnology company that focuses on finding and creating targeted treatments and diagnostic tools for neurodegenerative diseases like Alzheimer’s and ALS. The company, established in 2004, is based in Toronto, Canada.

Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis products. It employs a system based on data and experiments to present highly developed cannabinoid solutions in various product categories such as API, medical, pharmaceutical, and derma cosmetics. With vertical integration and a global presence, Avicanna is determined to harness the findings of scientific research on cannabis-based products with the aid of its internal research platforms and partnerships with renowned research institutions worldwide. Established in 2016, the company has its headquarters in Toronto, Ontario, Canada.

Harnessing the power of microbe-derived natural solutions to decarbonize the chemicals industry.

Theralase Technologies is a biopharmaceutical company that specializes in creating and selling patented laser technology for various medical applications. The company has two divisions: one focuses on producing therapeutic laser technology for commercial use, while the other focuses on researching and developing laser-based technologies for cancer cell destruction and other health conditions. The Therapeutic Laser Technology division works on creating non-invasive devices to treat pain, inflammation, and promote tissue healing. The Photo Dynamic Therapy division focuses on developing light-activated molecules and laser systems with strong anti-cancer and microbial sterilization properties.

Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies for medical conditions. These therapies are developed from the patient's own blood, making it a minimally invasive treatment option. The company's main product, ACP-01, is currently in Phase II clinical trials for critical limb ischemia. In addition to this product, Hemostemix is also working on developing other types of cell products, including bone cell precursors, myocardial cell precursors, and neural cell precursors.

ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based medical solutions. The company aims to promote the use of cannabinoids as a way to alleviate discomfort caused by chronic illness, treatment side effects, or age-related conditions. Its goal is to shift the focus from treating physical disease to taking care of overall well-being by promoting the adoption of plant-based medicine. Through the use of science, ZYUS is working to establish plant-based medicine as a standard of care for disease treatment and management. Established in 2018, ZYUS is based in Saskatoon, Saskatchewan.